Among the 550 patients of the BOLERO-2 trial with plasma samples taken at the start of treatment to analyse circulating tumour (ct)DNA, median PFS of patients carrying wild-type or mutant PIK3CA was similar in the combination and the placebo arm (Moynahan et al. 2017). Here, PIK3CA is linked to neoplasm.